TY - JOUR T1 - Antibody responses boosted in seropositive healthcare workers after single dose of SARS-CoV-2 mRNA vaccine JF - medRxiv DO - 10.1101/2021.02.03.21251078 SP - 2021.02.03.21251078 AU - Todd Bradley AU - Elin Grundberg AU - CODIEFY study team AU - Rangaraj Selvarangan Y1 - 2021/01/01 UR - http://medrxiv.org/content/early/2021/02/05/2021.02.03.21251078.abstract N2 - Current guidelines recommend that individuals who have had COVID-19 should receive the identical vaccine regimen as those who have not had the infection. This includes two doses of the mRNA platform vaccines (BNT162b2/Pfizer; mRNA-1273/Moderna) that are approved for use in the United States. In this brief report, we show that after a single dose of the Pfizer SARS-CoV-2 vaccine, individuals that had prior SARS-CoV-2 infection had significantly higher antibody levels than individuals that had no history of infection. This provides the rationale for changing vaccination policy to deliver only a single dose to individuals with recent SARS-CoV-2 infection that may free up additional doses for individuals that have no preexisting immunity to the virus. Future study of other immune parameters such as T cell response and durability of immune response should be rapidly undertaken in individuals that had COVID-19 prior to vaccination.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was funded through internal institutional funds from Childrens Mercy Research Institute and Childrens Mercy Kansas City. The work was also supported by a CTSA grant from NCATS awarded to the University of Kansas for Frontiers: University of Kansas Clinical and Translational Science Institute (# UL1TR002366) The contents are solely the responsibility of the authors and do not necessarily represent the official views of the NIH or NCATS. E.G. holds the Roberta D. Harding & William F. Bradley, Jr. Endowed Chair in Genomic ResearchAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The vaccinee biospecimens were collected under a clinical study at Childrens Mercy Kansas City and reviewed and approved by the Childrens Mercy IRB (#00001670 and #00001317).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesPrimary data are available from the authors at reasonable request. ER -